Themis Medicare Limited · NSE:THEMISMED
Themis Medicare — Q3 FY23 Earnings Presentation
31 slides from Themis Medicare's earnings presentation, Feb 9, 2023
Slide 1: Exchange filing cover letter for investor presentation
TML: CS: BSE/NSE CORR: 2022-23 9th February, 2023 Listing Department, Listing Department, BSE Limited, National Stock Exchange of India Ltd. P. J. Towers, Dalal Street, “Exchange Plaza”, Mumbai-400001 Bandra – Kurla Complex, Bandra – East, Mumbai- 400 051 Dear Sir/Madam, Sub: Subject: Investor Prese
Slide 2: Themis Medicare Ltd. Investor Presentation Q3 & 9M FY23
In every possibility lies an innate, latent power to change lives Themis Medicare Ltd. Investor Presentation Q3 & 9M FY23
Slide 3: Disclaimer
Disclaimer This presentation has been prepared by Themis Medicare Limited (the “Company” or “Themis” or “TML”) solely for information purposes and does not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in
Slide 4: Table of Contents
Table of Contents Company Overview Business Overview Financial Highlights Key Growth Drivers 3
Slide 5: Company Overview
Company Overview
Slide 6: Snapshot of Company
Snapshot of Company 1969 Strategic focus 3 4,000+ Themis Chemicals To become Leader in Hospital State of art Nationwide stockists' established Business in India manufacturing facilities network in India – 1 Formulations and 2 APIs 44+ Rs. 1,240 Cr Rs. 73 Cr Countries that we Export Market Cap PAT (A
Slide 7: Journey So Far…
Journey So Far… Themis Chemical established (now Themis Chemicals renamed Themis Medicare TML*) in partnership with Gedeon Limited Richter Ltd., Hungary Develops and introduces SEPGARDTM- Becomes 2nd Company in the world unique wound healing agent, 1st time in India and 1st in India to produ
Slide 8: Strong & Professional Management Team
Strong & Professional Management Team Dr. Dinesh S. Patel (Executive Chairman) Dr. Sachin D. Patel - (Managing Director & CEO) Doctorate in Medicinal Chemistry and Fellow of Royal Society of On board since 2004 & Managing Director & CEO since February 14, Chemistry, London, U.K. 2017 Expertise
Slide 9: Strong & Professional Management Team contd…
Strong & Professional Management Team contd… Ms. Manjul Sandhu (Independent Mr. Tushar Dalal (Chief Financial Officer) Director) Qualified Chartered Accountant and Associated with Themis group B.Com. Graduate and passed Intermediate examination for last sixteen years of Chartered Accountancy cou
Slide 10: Business Overview
Business Overview
Slide 11: Business Segments
Business Segments Formulations APIs 1 Formulations 2 Synthetic API’s 3 Facilities Haridwar Vapi Hyderabad Contributes 65% of Total Revenue (FY21- 22) Contributes 35% of Total Revenue (FY21-22) Hospital business Hospital Business Other Businesses Centre of growth of Total Revenue of Total Revenue 41%
Slide 12: Strong Business Model
Strong Business Model Businesswise Revenue – 9M FY22-23 Hospital 34% API & Co. Mkt Product 54% Trade Development (R&D) 12% 03 01 n 02 Businesswise Revenue – FY21-22 Hospital Business n API Business Critical Care Division API & Co. Hospital* Narcotics API Legacy Business Mkt 41% Instuition Bu
Slide 13: Hospital Business – Major Growth Driver
n Hospital Business – Major Growth Diver Hospital Portfolio can Include… Anti Infectives Sterile Injectibles Surgical Products Anesthesia Unique / Differentiated Products New Opportunities… Product Portfolio Current TML Portfolio To be Included Anesthesia Intensive Care Medical Devices Nutriti
Slide 14: TML Presence across Hospital Business
n TML Presence across Hospital Business Critical Care Division Institutions Intensive Care (CCD) and Narcotics 11 years old West and South part of India Proprietary TML Good presence in hospital to be fully operational from business Formulations Key Molecules December 2022 – will extend St
Slide 15: Hospital Sector - Trends and Statistics
n Hospital Sector - Trends and Statistics Medical Trends Hospital Statistics (In Nos.) Cost of Hospitalization Private Hospitals : 43,486 11.80 59,264 17.8% Spike primarily due to COVID 8% Earlier 2021 and associated co-morbidity 29,631 treatment protocols Market Intelligence Market ICUs Ventilators
Slide 16: Hospital Business Opportunity
n Hospital Business Opportunity Why Hospital Business Segment? Growing market - Themis has strong foot in door through Anesthesia Market Highly Fragmented unlike West where 3-4 players control 90% market share High Entry Barriers Large Product Portfolio needed to service this segment Takes t
Slide 17: API Segment – Overview & Strategy
API Segment – Overview & Strategy Major Existing Products Simvastatin - Largest selling API product for Company Out of Total Production – API (FY21-22) Fumagilline - Niche product In-House Consumption 2% Ketamine - DMF filings are planned in semi regulated markets Exports 98% Business Strategy
Slide 18: Vertically Integrated State of Art Manufacturing Capabilities
Vertically Integrated State of Art Manufacturing Capabilities Location Haridwar Hyderabad Vapi Particulars Artemis Biotech Themis Medicare Ltd. Themis Medicare Ltd. (Division of Themis Medicare Ltd.) Segment Formulations Synthetic APIs Synthetic APIs Injections Artemether, Ferracrylum, Lumefantrine,
Slide 19: Strong Research and Development Capabilities
Strong Research and Development Capabilities Continued Investment in R&D (Rs. Cr.) Business API Formulations Total Manpower 54 12 13.64 R&D 29 (Incl. 5 PhD) 6 (Incl. 1 PhD) 8.50 Analytical Lab 15 6 Development 5.16 5.28 4.59 Groups 5 3 3.43 Product in a year with 5–8 20-24 documentation FY16-17 FY17
Slide 20: Key Strengths
Key Strengths Strong Balance Sheet and growing Vertically Integrated profitability leading to better Cash Manufacturing Capabilities - Flows presence in Formulations and APIs Among top 3 players in Anesthesia Segment with complete range of portfolio 05 04 03 02 Presence in Corporate 01 Hospitals acr
Slide 21: Consolidated Financial Highlights
Consolidated Financial Highlights
Slide 22: Consolidated Quarterly Financial Highlights – Q3 FY22-23
Consolidated Quarterly Financial Highlights – Q3 FY22-23 Particulars (Rs. Cr.) Q3 FY22-23 Q3 FY21-22 Y-o-Y (%) Q2 FY22-23 Net Revenue 88.78 94.92 (6.47%) 91.00 Cost of Material Consumed 29.77 25.66 17.71 Purchase of SIT 6.26 7.85 5.29 Changes in Inventory (2.60) 5.17 4.53 Employee Expenses 16.62 13.
Slide 23: Consolidated Financial Highlights – 9M FY22-23
Consolidated Financial Highlights – 9M FY22-23 Particulars (Rs. Cr.) 9M FY22-23 9M FY21-22 Y-o-Y (%) Net Revenue 274.22 314.82 (12.90%) Cost of Material Consumed 65.73 86.51 Purchase of SIT 19.54 25.57 Changes in Inventory 5.30 9.31 Employee Expenses 48.42 38.33 Other Expenses 78.26 73.86 Total Expe
Slide 24: Consolidated Financial Highlights
Consolidated Financial Highlights 262.6 Revenue (Rs. Cr.)* Revenue (Rs. Cr.) 394.6 API Formulation 274.2 173.5 230.7 150.3 201.6 129.2 136.0 132.0 183.8 91.7 80.5 65.6 54.6 FY18-19 FY19-20 FY20-21 FY21-22 9M FY22-23 FY18-19 FY19-20 FY20-21 FY21-22 9M FY22-23 EBITDA (Rs. Cr.)** / Margin (%) PAT (Rs.
Slide 25: Annual Consolidated Financial Highlights – FY21-22
Annual Consolidated Financial Highlights – FY21-22 Particulars (Rs. Cr.) FY19-20 FY20-21 FY21-22 Net Revenue 201.59 230.67 394.61 Cost of Material Consumed 51.38 67.92 113.63 Purchase of SIT 15.30 11.55 31.45 Changes in Inventory (3.49) (0.90) 3.06 Employee Expenses 44.28 39.99 51.97 Other Expenses
Slide 26: Key Consolidated Balance Sheet Ratios
Key Consolidated Balance Sheet Ratios Working Capital Days Debt to Equity* 231 0.67 0.67 219 0.60 158 167 0.46 120 0.27 FY17-18 FY18-19 FY19-20 FY20-21 FY21-22 FY17-18 FY18-19 FY19-20 FY20-21 FY21-22 RoCE*** RoE** 25.34% 25.23% 13.50% 16.15% 14.69% 8.29% 10.93% 6.57% -1.27% FY17-18 FY18-19 FY19-20 F
Slide 27: Consolidated Balance Sheet as on 30th Sept '22
Consolidated Balance Sheet as on 30th Sept ’22 As on 31st As on 31st As on 30th As on 31st As on 31st As on 30th Rs. Cr. Rs. Cr. Mar’21 Mar’22 Sept’22 Mar’21 Mar’22 Sept’22 Shareholders Funds 218.51 287.49 317.89 Non Current Assets 185.67 213.62 229.45 Share Capital 9.19 9.20 9.20 Plant, Property &
Slide 28: Way Ahead
Way Ahead
Slide 29: Key Growth Triggers
Key Growth Triggers DISTRIBUTION NETWORK & PRODUCT PIPELINE RELATIONSHIPS Strong relationships with both First to Launch opportunities private and Govt. hospitals & Complex generic Pipeline in development institutions Generics – target to launch 10 – 12 Deep distribution network to product
Slide 30: Our Aspirations
Our Aspirations Vision & Position Provide hospitals and health systems ‘The Best Experience Leader business model” to ensure customer satisfaction Leadership in Anesthesia and Critical Care Strategy Focus on Hospital business APIs to be developed - in-house New Target Markets consumption and
Slide 31: Thank You
Thank You It takes one word to change the world “POSSIBILITY” For further information, please contact: Mr. Sangameshwar Iyer Mr. Amit Sharma / Ms. Disha Shah Tel: +91 9867726686 / 9699060134 Themis Medicare Ltd Adfactors PR Pvt Ltd Email: sangameshwar.iyer@themismedicare.com Email: amit.sharma@adfac